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1. Introduction
Diabetes, a chronic metabolic disorder, is a major threat 
nowadays worldwide (Shaw et al., 2010). The resultant 
hyperglycemia has been shown to be responsible for 
major diabetic complications like myopathy, retinopathy, 
nephropathy, and neuropathy which occur after a few years of 
onset of diabetes (Geraldes and King, 2010). It is believed that 
intra and extracellular changes by hyperglycemia can induce 
the signal transduction pathways which lead to the dysfunction 
of gene expression and proteins (Peppa et al., 2002). One of 
the most studied pathways; the diacylglycerol-Protein kinase 
C (DAG-PKC) pathway is activated by hyperglycemia in 
diabetes (Giacco and Brownlee, 2010). In this review, the 
functions of PKC and interconnected signaling changes in the 
growth of diabetic complications have been demonstrated. 
Protein Kinase C (PKC)
Serine/threonine kinases are ancestors of Protein kinase C 
that include 12 isoforms and are differentiated according 
to their domains that connect calcium or DAG; mutually 
they control the kinase activity (Schramm et al., 2012). On 
the basis of biochemical properties, PKC is divided into 
three types: conventional PKC, novel PKC, atypical PKC 
(Spiegel et al., 1996). Conventional PKC connects Ca2+ 
and DAG, novel PKC binds only DAG but not Ca2+, and 
atypical PKC binds none of them (Spiegel et al., 1996). 
For phosphorylation, the correct isoforms are required 
for the activation of conventional and novel PKC and the 
existence of cofactors such as DAG and Ca2+ (Schramm 
et al., 2012). Conventional and novel PKC are elevated 
by diacylglycerol (DAG), which in turn is amplified by 
the hyperglycemia in diabetes (Spiegel et al., 1996). When 
they are correctly phosphorylated, an increase in Ca2+ or 
DAG will rapidly allow cells to translocate (Gonçalves, 
2013). Quick and temporary increases of Ca2+ levels and 
DAG levels are frequently induced by cytokines during the 
activation of phospholipase C. Activation of PKC requires 
a sustained decrease of DAG, which involves the activated 
phospholipase D/C or DAGs de novo synthesis. All the 
above-mentioned pathways possibly participate in the 
activation of the DAG-PKC cascade in hyperglycemic and 
diabetic conditions (Michael et al., 2017).
Hyperglycemia Activates PKC
Diabetic state or hyperglycemia is responsible for the 
synthesis of a higher level of DAG via an elevation in the 
formation of glycolytic intermediate (dihydroxyacetone 
phosphate), which activates PKC (Tripathi and Srivastav, 
2006). The most studied pathway via which PKC induces 
diabetes is the DAG-PKC pathway (Nilsson, 2016). DAG 
is induced by hyperglycemia and leads to activation of 
different isoforms of PKC (Tripathi and Srivastav, 2006). 
de novo DAG synthesis can also be increased when glucose 
concentration is high during different metabolic pathways 
(Noh and King, 2007). Another mechanism by which DAG 
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synthesis can be increased is by inhibiting the glyceraldehyde-
3-phosphate dehydrogenase which is a glycolytic enzyme 
and results in upregulation of dihydroxyacetone phosphate 
to DAG by triggering higher metabolites from glycolysis 
into pathways of glucose (Nilsson, 2016). In diabetes, no 
changes in DAG levels were seen in a peripheral nervous 
system and central nervous system, but the disturbance in 
DAG levels was reported in vascular tissues and nonvascular 
tissues (Adibhatla et al., 2008). 
Activation of PKC Leads to Microvascular 
Complications
Hyperglycemia leads to diabetic complications and shows 
harmful effects on the human body. These complications are 
also due to higher levels of DAG-PKC, oxidative stress and an 
increased amount of glycation. Microvascular complications 
include retinopathy, nephropathy, neuropathy, and 
myopathy (Sheetz and King, 2002).
2. Retinopathy 
Nowadays, many mechanistic approaches have been 
found by which vascular tissue damage is induced by 
hyperglycemia. But the major pathway which leads to 
microvascular changes is due to elevation in levels of 
DAG-PKC (Karasu, 2010). The most significant 
regulatory system for activation and deactivation of the 
receptor pathway is pursued by adding or subtracting the 
phosphate group in intracellular protein, via phosphatases 
and kinases (Carri, 2014). Phosphorylation of many 
proteins at threonine or serine activates the physiological 
responses of the cascade which are mediated by PKC. 
Activation of PKC induces some changes i.e retinal 
leakage, permeability in endothelial, loss of capillary 
pericytes (Carri, 2014). In the initial stages of diabetic 
retinopathy, there is a loss of pericyte in retina around 
the capillaries followed by the weakening of capillary 
walls and which cause the leakage of fluid due to the high 
permeability of walls (Nassar et al., 2007). Recent studies 
demonstrate that two isoforms of PKC were activated i.e 
PKCβ and PKCδ through hyperglycemia. Further, these 
isoforms follow two different approaches; PKCβ will lead 
to cellular growth whereas PKCδ will give rise to cellular 
apoptosis (Nagpal et al., 2007). PKCβ after activation 
affects the vascular endothelial growth factor due to 
which the permeability of capillary walls increases and 
blood flow decreases which leads to the dysfunctioning of 
endothelial and cause macular edema (Dirks et al., 2006).
But PKCδ after activation shows two distinct pathways 
which ultimately lead to cellular apoptosis: 1) increase in 
production of reactive oxygen species and NF-κB activity 
which in turn activate the caspase 2) by upregulating the 
SHP-1 (protein tyrosine phosphatase) which will decrease 
the survival signaling pathway of platelet-derived growth 
factor both of these different approaches results in loss of 
pericyte as shown below in (Nassar et al., 2007) (Figure1). 
Figure 1: Hyperglycemia leads to cellular changes and retinopathy 
via activation of PKC.
3. Nephropathy
All the causes for risk factor and cardiovascular mortality 
rate worldwide are due to diabetic nephropathy which is 
the foremost reason for the end-stage renal disease (Dirks 
et al., 2006). Due to hyperglycemia, there is an increase 
in glomerular filtration rate in the kidney which elevates 
the glomerular filtration pressure (Tonneijck et al., 2017). 
Several approaches have been studied about the elevation 
of glomerular rate & pressure together with improved 
production of prostaglandin and angiotensin II. But the most 
important pathway leading to an increase in angiotensin 
II and in vasodilatory prostaglandin is via the DAG-PKC 
(Kaschina and Unger, 2003). In diabetes, hyperglycemia 
results in the formation of prostaglandin II which could 
be a cause of the activation of PKC. Another factor that 
results in the enhancement of the filtration rate is a higher 
level of nitric oxide. In diabetes, high amount of nitric oxide 
metabolites i.e. NO2 and NO3 is excreted through urine due 
to a high level of nitric oxide present in mesangial cell and 
in inducible nitric oxide synthase (Williamson et al., 1993). 
But in hyperglycemia both i.e. formation of nitric oxide 
and inducible nitric oxide synthase can be initiated by an 
agonist of PKC and blocked by its inhibitor which shows 
that in PKC induced diabetes there is an increase in levels 
of NO synthase (Caldwell et al ., 2003). Previous studies 
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demonstrated that there was a decrease in the production of 
nitric oxide and glomerular cGMP in glomeruli of diabetic 
rats which was restored by PKC inhibitor. Thus, this shows 
that possibly it might be due to an increase in the level of 
glucose-induced activated PKC which may supervise renal 
hemodynamics by elevating or declining the levels of nitric 
oxide production based on the sort of cells and period of 
hyperglycemia (Kaschina and Unger, 2003). Nephropathic 
studies also show that in glomerular mesangium there was an 
accumulation of extracellular matrix. This showed that there 
was an elevation in the oxidative stress due to hyperglycemia. 
In renal glomeruli, PKC activities were increased due to 
hyperglycemia which in turn upregulates many isoforms 
of the NADPH oxidases to generate too many oxidants 
(Marsigliante et al., 2001). This increased level of PKC 
leading to the activation of MAPK which upregulates the 
fibrotic growth factors. Several studies show that growth 
factors play a major function in the accumulation of ECM 
(Khera, 2006). 
Current studies have shown that there is an increase in 
vascular endothelial growth factor (VEGF) in the glomerulus. 
PKC is known to regulate activator protein-1 (AP-1), which 
promotes the binding of AP-1 to the promoter region of 
the VEGF gene. AGEs are also able to activate PKC, which 
further increase the expression of VEGF and this activated 
PKC is also responsible for many natural effects of VEGF 
(Prabhakar, 2004).
4. Neuropathy
Diabetes can cause nerve injury. Burning, numbness, pain 
in the feets all are the symptoms of diabetic neuropathy 
(Figure 2) (Argoff et al., 2006).
Figure 2: Neuropathy: Types & effects on various Organs.
It has been demonstrated that in nerves there is an existence 
of PKC-α, PKC-β1, PKC-β2, PKC-γ, PKC-δ and PKC-ε 
isoforms which were confirmed by immunochemical analysis 
(Cameron et al., 2005). Whereas the exact mechanisms of 
their action are not clear, but currently it is believed that 
these factors lead to reduced Na+–K+–ATPase activity and 
vasoconstriction, reduced endoneural blood flow (Martin 
et al., 2003). Diabetic rats have shown a decline in the 
activity of PKC in sciatic nerve tissue. There was also a 
reduction of Na+–K+–ATPase levels due to the involvement 
of PKC which could be due to a decline in nerve regeneration 
and conduction (Evcimen and King, 2007). It was also 
demonstrated that in diabetic mice there was a reduction 
in membrane-associated PKC activity and when treated 
with PKC inhibitor sustained Na+–K+–ATPase action was 
observed (Marsigliante et al., 2001). Preclinical study also 
suggested that specific PKC inhibitors were used to recover 
the neural function i.e inhibition of PKC in nerves boost the 
blood flow (Brooks et al., 2008) (Figure 2).
5. Cardiovascular Disease
The diabetic patient suffers from diastolic dysfunction, 
interstitial fibrosis, hypertension, and congestive heart 
failure (Naito et al., 2001). In hyperglycemia, activated 
PKC gives rise to cardiomyopathy via inhibiting metabolic 
actions of insulin. In the myocardium, insulin loss is 
coupled with lower basal expression factor-1 of hypoxia, 
which strikes VEGF actions in the myocardium (Valko 
et al., 2007). In comparison to normal patients other than 
diabetes, diabetic patients with cardiomyopathy have shown 
declined expression of VEGF. Immunoblotting showed an 
increase in levels of PKC-β1 and PKC-β2 in the failed heart 
of humans as compared to a healthy live heart (Geraldes 
and King, 2010). Previous studies show that when the 
human heart was treated with LY333531 which is a PKC-β 
inhibitor then it leads to the inactivation of PKC (Sakata et 
al., 2015). In hyperglycemic condition, there is an increase 
in levels of PKC-α, PKC-β1 and PKC-β2 isoforms in the 
heart (Arimura et al., 2004). In diabetic heart, both PKC–β 
inhibitor and ACE improve the gene profile & PKC activity 
(Naito et al., 2001).The isoforms of PKC i.e. PKC-α and 
PKC-ε also have important functions in cardiomyopathy 
and elevate the contractility of the heart leading to less 
vulnerability to heart attacks (Arimura et al., 2004).
PKC Inhibitors
The role of PKC in the development of diabetic complications 
has become an area of interest for research (Gennas et al., 
2009). There are many specific and non-specific compounds 
that have inhibitory action for PKC (Khera, 2006). Non-
specific inhibitors are not in use because clinically they 
have been proven as toxic while specific inhibitors have 
shown great therapeutic use (Khera, 2006). The function 
of different PKC isoforms was demonstrated by observing 
the binding of proteins to specific sites after activation and 
translocation (Aielleo, 2002). Several PKC inhibitors that 
are being studied are Midostaurin (PKC412, CGS41251, 
N-benzoyl staurosporine), UCN-01 (KW-2401, 
NSC-638850), Lestaurtinib (CEP-701, KT-5555), 
Ro-31-8220 and Go6976 (Shen et al., 2003; Wang et al., 
2008; Wang et al., 2009. Ro-32-0432, PKC-α inhibitor, was 
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found to be effective in AGE mediated damage in diabetic 
nephropathy. Ruboxistaurin mesylate (LY333531), a potent 
PKCβII inhibitor, has been evaluated in clinical studies for 
diabetic complications (Vinik, 2005; Joy et al., 2005; Aiello, 
et al., 2006). Several clinical benefits such as reduced retinal 
vascular leakage and improved visual acuity in diabetic 
macular edema, however, phase III clinical endpoints 
did not reproduce the desired results (American Diabetes 
Association, 2005). Vitamin E, a selective inhibitor, also has 
an inhibitory effect on the DAG–PKC but does not inhibit 
PKC directly (Aielleo, 2002). Vitamin E has shown a great 
effect in nephropathy and retinopathy (Kizub et al., 2014). 
Preclinical Studies Exploring The Role of PKC in 
Diabetes (Table 1)
Modulation of PKC activity for clinical drug development 
is vital as isozyme specific disruptions in PKC activity have 
been identified in human disease states such as diabetes 
(Nishikawa et al., 2000, Geraldes et al., 2010). Therefore, 
understanding the basic biology of the disease and multiple 
pathways involved in the progression of the disease is 
essential for therapeutic progress in this  field. As shown 
in table 1, various preclinical studies conducted on PKC 
inhibitors in diabetes and related complications have been 
summarised.




1 Protein kinase C inhibition and diabetic 
retinopathy: a shot in the dark at translational 
research
Donnelly et al studied that activated PKC leads to diabetic retinopathy is one of the 
major complications of hyperglycemia can be treated with drugs that can lower the 
cholesterol levels combined with ACE inhibitors (Donnelly et al., 2014).
2 The role of protein kinase C activation and 
the vascular complications of diabetes.
Evcimen and King studied that activated PKC results in diabetic retinopathy, 
nephropathy, and cardiovascular disease. So, to cure these complications, use of 
PKC inhibitors has been introduced with great therapeutics approaches (Evcimen 
and King, 2007). 
3 The role of protein kinase C activation in 
diabetic nephropathy
Noh and king concluded that PKC plays a major role in diabetes nephropathy 
(Noh and king, 2007) 
4 Ruboxistaurin: PKC-β inhibition for 
complications of diabetes
Danis and Sheetz demonstrated that activated PKC plays a major role in the 
development of diabetic complications and they concluded the beneficial effect of 
PKC-β inhibitor against complications (Danis and Sheetz, 2009).
5 Activation of Protein Kinase C Isoforms and 
Its Impact on Diabetic Complications
Geraldes and King presented that one of the chronic adverse effects of 
hyperglycemia is the activation of PKC which cause vascular dysfunction and 
ultimately worsen the diabetic complications (Geraldes and King, 2010).
6 Old Suspect-New Evidence The Role of 
PKCβ in Diabetes Mellitus–Accelerated 
Atherosclerosis
Butcher and Galkina suggested the potential effects of hyperglycemia-induced 
atherosclerosis via PKCβ signaling pathway (Butcher and Galkina, 2013).
7 Hyperglycemia-induced Oxidative Stress 
and its Role in Diabetes Mellitus related 
cardiovascular diseases
Vanessa et al demonstrated that hyperglycemia is associated with many intercellular 
pathways which can induce cardiovascular changes and exploring many beneficial 
antioxidant therapies to prevent complications (Vanessa et al., 2013).
8 Protein kinase C in enhanced vascular tone in 
diabetes mellitus
Kizub et al studied that the microvascular complications of diabetes are mainly due 
to hyperglycemia which ultimately activate protein kinase C (Kizub et al., 2014).
9 Role of protein kinase C in podocytes and 
development of glomerular damage in 
diabetic nephropathy
Teng et al suggested that in diabetes the glomerular injury is due to the activation 
of PKC (Teng et al., 2014).
10 Increases in PKC gamma expression in 
the trigeminal spinal nucleus is associated 
with orofacial thermal hyperalgesia in 
streptozotocin-induced diabetic mice
Xie et al studied that in diabetes the isoform PKCγ is involved and can be dealt 
with early insulin management (Xie et al., 2015).
11 PKC-α triggers EGFR ubiquitination, 
endocytosis and ERK activation in podocytes 
stimulated with high glucose
Lei et al demonstrated that hyperglycemia leads to activation of PKC-α which 
contributes to podocyte damage (Lei et al., 2017). 
12 Berberine ameliorates diabetic neuropathy: 
TRPV1 Modulation by PKC pathway
Zan et al demonstrated that diabetic pain can be cured by berberine which 
suppresses and blocks the activation of the PKC pathway (Zan et al., 2017)
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13 Impairment of neurovascular coupling in 
Type 1 diabetes mellitus in rats is prevented 
by pancreatic islet transplantation and 
reversed by a semi selective
PKC inhibitor
Vetri et al concluded that DM can be prevented by PKC-α/β/γ inhibitor or via 
transplantation of pancreatic islet (Vetri et al., 2017). 
14 Pueraria tuberosa extract inhibits iNOS and 
IL-6 through suppression of PKC-α and NF-
kB pathway in diabetes-induced nephropathy
Shukla et al demonstrated that in diabetic nephropathy PTY-2r shows the 
nephroprotective effect via the down-regulation of PKC-α pathway (Shukla et al., 
2018).
Other Therapeutic Implications and Role of PKC
Current studies have shown that in cardiac patients there is 
an elevation in levels of PKCα which leads to many heart 
diseases like heart attack and atherosclerosis. Ro 32–0432 
and Ro 31–8220 are the PKC inhibitors which are used to 
reduce the levels of PKCα as also observed with the reduced 
the levels of PKCα in left ventricle tissues which have 
lowered the risk of cardiac diseases (Weeks and McMullen, 
2018). In manic and bipolar disorder patients, the levels of 
PKC are elevated so to reduce the manic symptoms the PKC 
inhibitors are used. Recent findings have shown that PKC 
inhibitors i.e tamoxifen have the same effects as compared 
to valproate and lithium (Zarat and Manji, 2009). As data 
obtained from preclinical studies showed that Phorbol ester 
and Bryostatin-1 are the potent PKC activator which helps 
in the reduction of tumor growth and is a modulator of many 
signaling pathways. Many PKC inhibitors are still under 
preclinical studies like Quercetin, Tamoxifen, Safingol, and 
LY900003, etc. Some of them are under phase II and III 
clinical trials (Sherova et al., 2006). In many clinical trial 
phases, the various PKC inhibitors together with partially 
specific or specific inhibitors have been applied (Capdeville 
et al., 2002).
Clinical Perspective of PKC
In leukemia patients, phase I studies were conducted to see 
the positive outcomes of paramethoxymethyamphetamine 
(PMA) and additionally PMA in combination with 
25-dihydroxy vitamin D3, or sodium butyrate was also 
tested on patients. The results suggested that drugs given in 
combination were more effective as compared to PMA alone 
(Diaz et al., 2015). Bryostatin 1 has been used in clinical 
trials which is one of the PKC modulators and downregulates 
some PKC isozymes. The anti-tumour activity was shown by 
Bryostatin 1 in phase I studies but Phase II studies have not 
yielded clinically usefull results as it was expected. Phase II 
studies combining bryrostatin 1 with other cytotoxic agents 
have not shown any efficacy and so it has failed to move in 
further trials (Koya, 2014). As the same case with safingol 
which is a specific PKC inhibitor and has shown cytotoxic 
effects when given in combination with conventional 
chemotherapy agents where as safingol alone has a nominal 
effect on tumor cell growth (Table 2) (Zhang et al., 2014).
Table 2: Clinical Studies Exploring The Role of PKC In Diabetes. 
S. 
No
DRUG & EFFECT CLASS OF AGENT PHASES OF CLINICAL TRIALS
1 PMA (TPA)
PKC activator




Indolocarbazoles Preclinical phase II trials in small cell lung carcinoma, 
melanoma, and lymphomas (Aielleo, 2002).
3 Bryostatin-1
(PKC activator)
Macrocyclic lactones Phase II trials as a single agent and in combinations (Koya, 
2014).
4 Quercetin
(PKC and other kinases inhibitor)
Flavonoid Limited phase I trials (Koya, 2014).
5 Tamoxifen
(PKC inhibitor)
Antiestrogens Treatment of breast cancer (Weeks and McMullen, 2018).
6 Safingol
(PKC inhibitor)
Lipid analogs Phase II LY900003 topical treatment (BOONE. 2013).
7 ISIS 3521 (LY900003) 
aprinocarsen)
(PKC specific inhibitor)
Antisense oligonucleotides Phase II clinical trials in combination with 5-fluorouracil-
leucovorin, cisplatin-gemcitabine, docetaxel, phase III 
with carboplatin, paclitaxel (Chua et al., 2005)
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Conclusion
In this review, we studied hyperglycemia is a key factor 
responsible for diabetic complications which shows harmful 
effects on the human body and leads to activation of PKC. 
Microvascular complications like retinopathy, nephropathy, 
neuropathy, and myopathy occur due to chronic pathological 
condition leading to a higher level of DAG-PKC, oxidative 
stress and an increased amount of glycation. Hence, it is 
concluded that PKC is a therapeutic approach for treating 
vascular diabetic complications as clinical trials have shown 
beneficial effects of selective PKC inhibitors in diabetic 
complications. 
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